All In Biotech

Drug Trial Radar · NCT07041801

Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells

Phase I/II Clinical Study on the Safety, Efficacy, Pharmacodynamics and Immunogenicity of Human Umbilical Cord Mesenchymal Stem Cell Injection (hUCMSCs) in the Treatment of Patients With Moderate to Severe Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Feb 15, 2025

Primary completion

Sep 5, 2027

Study completion Dec 28, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the safety and efficacy of allogeneic umbilical cord-derived stem cell therapy in treating patients with moderate to severe systemic lupus erythematosus.

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • hUC-MSCs treatment (low dose)Drug

    patients will receive conventional therapy plus low dose hUC-MSCs treatment,The dosage is 1E6 cells/kg.

  • hUC-MSCs treatment (medium dose)Biological

    patients will receive conventional therapy plus medium dose hUC-MSCs treatment,The dosage is 3E6 cells/kg.

  • hUC-MSCs treatment (high dose)Biological

    patients will receive conventional therapy plus high dose hUC-MSCs treatment,The dosage is 5E6 cells/kg.

  • PlaceboDrug

    patients will receive conventional therapy plus Placebo

  • hUC-MSCs treatment (Double dose)Biological

    Double dosing is selected by the investigators and the sponsor based on the data from the single-dose part of the study. One superior dose is chosen for multiple dosing (tentatively set at 3E6 cells/kg, administered twice with an interval of 4 weeks; the actual dose, frequency and interval of multiple dosing can be adjusted according to the available data). During the trial, stable standard treatment is allowed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: day 1 to day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shenzhen Beike Bio-Technology Co. Ltd.

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.